These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India. Maron BJ Am J Cardiol; 2015 Jul; 116(2):332-4. PubMed ID: 25983127 [TBL] [Abstract][Full Text] [Related]
3. Hypertrophic cardiomyopathy is a global disease including China. Cheng TO Int J Cardiol; 2008 Jun; 127(1):1-4. PubMed ID: 18053599 [No Abstract] [Full Text] [Related]
4. 'End-stage' hypertrophic cardiomyopathy: from mystery to model. Yacoub MH; Olivotto I; Cecchi F Nat Clin Pract Cardiovasc Med; 2007 May; 4(5):232-3. PubMed ID: 17457348 [No Abstract] [Full Text] [Related]
5. Dealing with a special group: hypertrophic cardiomyopathy. Etiology and prevalence: what is known today. Komajda M Rev Port Cardiol; 1999 Sep; 18 Suppl 5():V41-4. PubMed ID: 10582456 [No Abstract] [Full Text] [Related]
6. [Congenital heart diseases in adult age and primary cardiomyopathies at the referral centers]. Dolara A Minerva Cardioangiol; 2004 Aug; 52(4):345-6. PubMed ID: 15284684 [No Abstract] [Full Text] [Related]
7. Hypertrophic cardiomyopathy in China: from bench to bedside. Cheng TO Int J Cardiol; 2008 Nov; 130(2):121-4. PubMed ID: 18684519 [No Abstract] [Full Text] [Related]
8. Hypertrophic cardiomyopathy in the community: why we should care. Cecchi F; Yacoub MH; Olivotto I Nat Clin Pract Cardiovasc Med; 2005 Jul; 2(7):324-5. PubMed ID: 16265538 [No Abstract] [Full Text] [Related]
9. Recognition of hypertrophic cardiomyopathy as a contemporary, relatively common, and treatable disease (from the International Summit V). Maron BJ Am J Cardiol; 2014 Feb; 113(4):739-44. PubMed ID: 24484864 [No Abstract] [Full Text] [Related]
11. Bernard J. Gersh, Mayo Clinic, Rochester, MN, USA, provides a transatlantic perspective on the 2014 European Society of Cardiology Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy. Ozkan J Eur Heart J; 2015 Jan; 36(1):7-8. PubMed ID: 25723003 [No Abstract] [Full Text] [Related]
12. Differences in Characteristics and Outcomes Between Patients With Hypertrophic Cardiomyopathy From Asian and European Centers. Tjahjadi C; Butcher SC; Zegkos T; Sia CH; Hirasawa K; Kamperidis V; Ngiam JN; Wong RCC; Efthimiadis G; Bax JJ; Delgado V; Ajmone Marsan N J Am Heart Assoc; 2022 May; 11(10):e023313. PubMed ID: 35574964 [No Abstract] [Full Text] [Related]
13. Hypertrophic cardiomyopathy in China: three decades of progress. Cheng TO Int J Cardiol; 2005 Apr; 100(3):493-4. PubMed ID: 15837095 [No Abstract] [Full Text] [Related]
14. Prevalence of hypertrophic cardiomyopathy in China. Cheng TO Chin Med J (Engl); 2004 Oct; 117(10):1600. PubMed ID: 15536665 [No Abstract] [Full Text] [Related]
15. Hypertrophic cardiomyopathy in the developing world: focus on India. Maron BJ; Kalra A Eur Heart J; 2014 Sep; 35(36):2492-5. PubMed ID: 25038775 [No Abstract] [Full Text] [Related]
16. Obstructive sleep apnea and hypertrophic cardiomyopathy: obiter dictum or more? Jan MF; Tajik AJ J Am Coll Cardiol; 2014 Dec; 64(23):2560-2. PubMed ID: 25500246 [No Abstract] [Full Text] [Related]
17. Reply: Obstructive sleep apnea and hypertrophic cardiomyopathy: obiter dictum or more? Maron BJ; Ommen SR; Semsarian C; Spirito P; Olivotto I; Maron MS J Am Coll Cardiol; 2014 Dec; 64(23):2562. PubMed ID: 25500247 [No Abstract] [Full Text] [Related]
18. The New European Society of Cardiology guidelines on hypertrophic cardiomyopathy. Elliott P Heart; 2015 Apr; 101(7):506-8. PubMed ID: 25700430 [No Abstract] [Full Text] [Related]
19. Comments on the 2014 ESC Guidelines on the diagnosis and management of hypertrophic cardiomyopathy. A critical view from the perspective of Spanish cardiology. ; ; Rev Esp Cardiol (Engl Ed); 2015 Jan; 68(1):4-9. PubMed ID: 25553935 [No Abstract] [Full Text] [Related]